Post-earnings recap
Reported
Fri, Nov 6, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Krystal Biotech is still facing challenges, as evidenced by the missed EPS target. The stock reacted negatively, dropping 6.42%, likely due to investor concerns over the company's current performance and lack of revenue updates. Without guidance, investors may remain cautious about the company's near-term prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.49 | N/A | -11.87% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed concerns about market conditions affecting performance. They reiterated their commitment to long-term goals despite short-term setbacks.
Management highlighted ongoing challenges in the current market environment.
They emphasized the need for continued focus on product development.